Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers

Inclusion Criteria: * To have at least one of the following three risk factors: * Tumour classified T3 or T4 * Gleason score 8-10 * Prostate-specific antigen (PSA) level \> 20 * Performance status score of 0-1. * Patients must sign a consent form before the start of the study. * No evidence of regional disease: clinically negative regional adenopathies are revealed by imaging (computed axial tomography \[CAT\] scan, magnetic resonance imaging \[MRI\], lymphography) or surgical staging or negative pelvic node dissection. * No distant metastasis. These patients must all have a negative bone scan 12 weeks prior to randomization. * Hormonal therapy is allowed up to a maximum of two months before the consent form is signed, as long as the initial work-up was done, including having the requested deadlines respected. * Patients with a previous history of cancer are eligible on the condition that they have not had any disease progression for more than five years. * The patient must be available for treatments and follow-up visits. * Treatments must start in the three weeks following randomization. Exclusion Criteria: * Severe medical or psychiatric problems that could compromise study compliance. * Chronic hepatic disease, abnormal hepatic functions, i.e. aspartate aminotransferase, alanine aminotransferase \> 1.5 times the upper normal limit.